Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The site footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:18:45.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T14:09:32.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content, indicating restricted access to the CRETA trial details on ClinicalTrials.gov. This reflects an access issue rather than a substantive update to the study information.
    Difference
    20%
    Check dated 2026-09-19T19:18:13.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    The page revision updated the version from v3.6.5 to v3.6.6, signaling a minor update to the record. No substantive changes to the study details are indicated.
    Difference
    0.0%
    Check dated 2026-08-29T18:29:08.000Z thumbnail image
  6. Check
    73 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5, replacing the previous v3.6.4, indicating a small update to the page template or content management system.
    Difference
    0.0%
    Check dated 2026-08-08T09:37:19.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    The page revision was updated to v3.6.4, replacing the previous v3.6.3. This indicates a maintenance update to the page rather than a change to study data or functionality.
    Difference
    0.0%
    Check dated 2026-07-25T06:22:42.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.